Loading...
XNYSCVM
Market cap18mUSD
Jan 14, Last price  
0.40USD
1D
-2.41%
1Q
-58.90%
Jan 2017
-75.90%
Name

CEL-SCI Corp

Chart & Performance

D1W1MN
XNYS:CVM chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
21.20%
Rev. gr., 5y
-2.32%
Revenues
0k
325,479269,925125,45757,0435,06580,093153,300956,154254,61000657,377285,05569,020476,556462,754558,664000
Net income
0k
P
-4,199,722-3,039,607-7,939,210-9,629,657-7,703,415-40,910,03010,483,429-25,712,343-15,477,310-9,170,947-27,366,265-34,674,646-11,466,498-14,363,287-31,837,205-24,692,724-32,223,336-39,187,563-38,267,6910
CFO
-23m
L+25.26%
-4,397,793-3,069,372-8,675,827-4,890,077-7,941,790-6,513,309-12,804,207-22,555,411-12,190,013-13,548,580-22,928,019-23,833,333-23,082,493-13,791,894-13,389,558-16,320,685-15,276,161-18,787,016-18,240,951-22,848,561
Earnings
Feb 12, 2025

Profile

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.
URL
https://cel-sci.com/
IPO date
Dec 08, 1983
Employees
43
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑092022‑092021‑092020‑092019‑092018‑092017‑092016‑092015‑09
Income
Revenues
Cost of revenue
35,434
39,946
Unusual Expense (Income)
NOPBT
(35,434)
(39,946)
NOPBT Margin
Operating Taxes
1,567
Tax Rate
NOPAT
(35,434)
(41,513)
Net income
(38,268)
-2.35%
Dividends
Dividend yield
Proceeds from repurchase of equity
6,552
(38)
BB yield
-11.79%
0.03%
Debt
Debt current
1,969
1,731
Long-term debt
25,174
28,875
Deferred revenue
Other long-term liabilities
125
125
Net debt
22,998
7,934
Cash flow
Cash from operating activities
(22,849)
(18,241)
CAPEX
(362)
(661)
Cash from investing activities
(372)
5,491
Cash from financing activities
4,694
(638)
FCF
(31,741)
(37,813)
Balance
Cash
4,146
22,672
Long term investments
Excess cash
4,146
22,672
Stockholders' equity
(486,617)
(454,463)
Invested Capital
513,529
502,054
ROIC
ROCE
EV
Common stock shares outstanding
44,480
43,149
Price
1.25
-59.55%
3.09
-71.88%
Market cap
55,600
-58.30%
133,330
-70.16%
EV
78,598
141,264
EBITDA
(31,476)
(36,117)
EV/EBITDA
Interest
675
1,081
Interest/NOPBT